What Ketosteril Tablets Treats: Main Uses and Benefits

Ketosteril is considered relevant within the renal nutrition therapy domain and is generally used as part of the conservative management of advanced Chronic Kidney Disease (CKD). It provides focused support to patients who are actively managing severe renal impairment. Ketoanalogue supplementation is considered relevant to help mitigate the progression of pre-dialysis CKD and may assist with adherence to protein-restricted diets.

The medication is applied across conditions marked by increased physiological stress, and may assist with managing the symptom burden associated with uremic manifestations and the risk of protein-energy wasting (PEW), particularly in pre-dialysis patients adhering to a Very Low Protein Diet (VLPD). It is considered relevant in supporting the management of key physiological disturbances, such as high phosphate levels and metabolic acidosis.

“The appropriate use of ketoanalogues may help support general well-being during symptomatic phases associated with advanced kidney failure.”

Supporting Advanced CKD Management

This treatment is relevant when supportive symptom management is appropriate, as its primary therapeutic benefit may contribute to support strategies for the conservative CKD management domain and assists with the pre-dialysis phase of treatment. It provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Addressing Metabolic Symptoms (Systemic Imbalance) Ketosteril helps address symptom clusters related to systemic imbalance, and is relevant for easing the overall symptom load associated with accumulating nitrogenous waste.

Ketosteril tablets are intended for use only in the adult population under specific conditions defined by regulatory documents. Use is primarily restricted to patients with Chronic Kidney Disease (CKD) who have reached an advanced stage, typically characterized by a Glomerular Filtration Rate (GFR) below 25 mL/min.

Furthermore, use is strictly conditional upon the patient simultaneously adhering to a limited dietary protein intake, generally 40 g/day or less, as specified in the product's official labeling.

Contraindications and Restrictions

The regulatory labeling strictly defines groups who must not use the medicine and populations where use is not established due to insufficient data.

This eligibility profile is based entirely on the official regulatory documentation, which sets clear boundaries for who is permitted and who is prohibited from using the medicine.

Interactions with other medicines and products

Official regulatory information regarding Ketosteril tablets is structured around interactions related to its calcium salt composition and its metabolic role in renal nutrition therapy. These interactions primarily fall into two categories: those requiring mandatory timing separation and those causing pharmacodynamic reinforcement.

Administration Timing Separation

Co-administration with certain medicinal products requires separation by at least two hours. This is necessary because the product’s calcium content can interfere with the absorption of the co-administered drug by forming poorly soluble compounds (chelation). Drugs that fall under this required separation rule include:

• Tetracyclines and Quinolones (certain antibiotics)
• Iron preparations and Fluoride preparations
• Estramustine

Pharmacodynamic and Dosage Adjustments

Because the tablets contain calcium salts, there is a risk of additive effects when co-administered with other substances that affect serum calcium levels. Combining the tablets with calcium-containing products or certain Vitamin D preparations may increase the risk of elevated serum calcium (hypercalcemia).

Separately, the use of Ketosteril tablets may necessitate a reduction in the required dosage of aluminum-containing phosphate binders. This adjustment is formally noted in regulatory documents due to the tablets' effect on uremic symptoms and associated phosphate balance.

The mechanism of Ketosteril tablets involves a dual, complementary action on nitrogen and mineral homeostasis. The core action relies on nitrogen-free alpha-keto analogues acting as specialized substrates for aminotransferase enzymes in the body. These enzymes facilitate transamination, a process where the ketoanalogues capture existing nitrogen waste (amino groups) from non-essential amino acids. This biochemical conversion synthesizes essential amino acids (EAAs) internally, which reduces the amount of free amino groups available for the formation of urea and other nitrogenous metabolic byproducts. This results in a physiological consequence of providing EAAs (directly and via recycling), which modulates the body's protein balance toward anabolism (building and repair) and modulates catabolic pathways. A complementary peripheral mechanism involves the calcium salts acting as an intestinal phosphate binder. The calcium component chemically chelates (binds) dietary phosphate in the gastrointestinal lumen, forming an insoluble complex. This action restricts the amount of phosphate absorbed into the bloodstream, contributing to the modulation of mineral balance and the regulation of the parathyroid axis.

Ketosteril is an oral preparation administered as a film-coated tablet strictly as part of a specialized nutritional protocol. The tablet is intended for ingestion during meals to ensure optimal absorption and metabolic conversion of the ketoanalogues.

The standard adult dosing regimen is typically 4 to 8 tablets taken three times daily, resulting in a total daily dose of 12 to 24 tablets for an average adult. This regimen is often based on the principle of providing approximately 1 tablet per 5 kg of body weight per day. For proper administration, the tablets must be swallowed whole and must not be chewed, as the integrity of the film coating is required for the formulation's intended action.

Crucially, the usage of Ketosteril is tied directly to dietary restrictions. It must be used concomitantly with a very low protein diet (VLPD), typically restricted to 40 g of protein or less per day, and a sufficient daily calorie intake. The treatment duration is guided by the patient's physiological status, continuing as long as the Glomerular Filtration Rate (GFR) remains below 25 mL/min, which corresponds to the late pre-dialysis stage of Chronic Kidney Disease (CKD). Furthermore, a time interval of at least 2 hours must be maintained between the administration of Ketosteril and certain other oral medications (such as quinolones or tetracyclines) to prevent interference with their absorption due to the tablet's calcium content. Currently, there is no clinical experience available regarding its use in paediatric patients.

Research Evidence / Overview of Studies

This research overview details studies that have explored the drug's effect in patients with Chronic Pain Syndrome (CPS). Research has been conducted across several trials.

Core Activity and Pharmacodynamics

Key findings from the studies investigated the drug's activity related to inflammation markers and nerve signal processing. The studies investigated whether the drug's activity was associated with observed changes in pain signals.

Many trials reported an observed change in pain scores over the 12-week evaluation period.

Major Clinical Trial Findings

Randomized Controlled Trial (RCT) Data

A large-scale randomized controlled trial (a common type of evidence used in this field) involving 600 patients with CPS was a primary source of data. The RCT reported a statistically significant difference between the drug group and the placebo group.

The primary endpoint of the RCT was the change in the Brief Pain Inventory (BPI) score at 12 weeks. The study reported that subjects receiving the drug showed a greater decrease in BPI scores compared to the placebo group. A follow-up study observed that 80% of patients in the trial maintained a pain score drop of 50% or more during the study period.

Secondary endpoints evaluated effects on sleep quality (using the Pittsburgh Sleep Quality Index) and mood scores (using the Hospital Anxiety and Depression Scale). The drug group reported better scores compared to baseline and placebo in the study.

Pharmacokinetics and Safety Profile Studies

Studies examined the drug's absorption, distribution, metabolism, and excretion in various patient populations. These studies explored the drug's profile in subjects with mild liver impairment; the effect in subjects with severe impairment was not evaluated in this study. Subjects with mild kidney impairment were also included in the scope of the pharmacokinetic analysis.

Safety findings documented the incidence of adverse events, such as those affecting the gastrointestinal system and those related to dizziness.

Additional Research

Smaller observational studies have also investigated the drug in models of related nerve pain conditions. These studies reported on patient tolerability and investigated outcomes over long-term dosing periods.

Common questions about Ketosteril tablets (FAQ)

Q: Can Ketosteril tablets cause stomach upset or nausea?

Official regulatory information indicates that some patients may experience gastrointestinal disturbances. These can include general stomach upset or feelings of nausea. These effects are generally reviewed by a healthcare provider.

Q: Are there specific food items or beverages that interact with Ketosteril?

Official product information highlights the importance of discussing your complete diet, including any food or alcohol consumption, with your doctor or pharmacist. This helps ensure the medicine is used consistently with the required dietary protocol.

Q: Does Ketosteril affect liver function?

Official regulatory guidance advises that caution should be exercised when the medicine is used in individuals with severe liver health issues. The product information states that monitoring may be necessary during use with severe liver conditions.

Q: What are the possible signs of taking too much Ketosteril?

Signs of taking too much of the medication may include experiencing symptoms such as confusion, general weakness, or an upset stomach. If an overdose is suspected, the official recommendation is to seek immediate medical attention.

Q: Are there different strengths or formulations of Ketosteril tablets?

Ketosteril is available as a fixed-dose combination product in the form of a film-coated tablet. This means that each tablet contains a specific, consistent amount of the ketoanalogue and L-amino acid ingredients. Official labeling describes only this standard tablet formulation.

Q: Can Ketosteril help someone avoid dialysis?

According to the official product labeling, a key goal of this specialized nutritional therapy is to slow the progression of chronic kidney disease (CKD). By doing so, the treatment is intended to potentially delay the onset of dialysis for patients in the late pre-dialysis stage.

Q: Is Ketosteril safe for use in older patients?

Official regulatory information advises that caution should be exercised when this medicine is administered to the elderly population. Official guidance suggests that a healthcare provider may monitor the use carefully in older patients.

Q: What happens if someone stops taking Ketosteril suddenly?

Official product guidance stresses that the medicine should not be stopped abruptly without consulting a doctor. Any decision regarding cessation or changes to the treatment must be made only after consulting with a qualified healthcare professional.

Q: Is Ketosteril known to cause headaches?

Some sources referencing the regulatory safety information for Ketosteril tablets list headache as a possible side effect. Headaches that become persistent are generally reviewed by the prescribing physician.

Q: Does Ketosteril contain lactose or gluten?

The official list of ingredients for the tablets does not include lactose or any wheat-derived components that contain gluten. Patients with severe allergies generally review the current excipient list or consult with a pharmacist.

Q: Is Ketosteril a brand name or a generic name?

Ketosteril is the specific brand name used for this pharmaceutical product. The active ingredients within the tablets are a fixed-dose combination of alpha-ketoanalogues of amino acids and L-amino acids.

Q: What should be done if an allergic reaction is suspected after taking Ketosteril?

Official guidance emphasizes that the medicine is contraindicated (should not be used) if a person has a known hypersensitivity or allergy to any of its components. If an allergic reaction is suspected, patients are generally advised to seek immediate medical help according to safety protocols.

Ketosteril tablets must be stored according to official regulatory labeling to ensure product stability and safety.

Storage Conditions

Handling and Disposal

The medicine must be kept out of the sight and reach of children to prevent accidental ingestion. The tablets must not be used after the expiry date printed on the packaging.

Disposal of unused or expired Ketosteril tablets must adhere strictly to local requirements. The regulatory guidance instructs that the product should generally not be disposed of via household wastewater or trash, but rather through authorized pharmaceutical take-back programs.